MB
VERA icon

MPM BioImpact’s Vera Therapeutics VERA Stock Holding History

MPM BioImpact’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-563,075
Closed -$16.4M – 52
2025
Q3 		$16.4M Hold
563,075
– – 2.68% 16
2025
Q2 		$13.3M Buy
563,075
+147,356
+35% +$3.31M 2.3% 20
2025
Q1 		$9.99M Buy
415,719
+157,931
+61% +$5.07M 1.72% 27
2024
Q4 		$10.9M Buy
+257,788
New +$11.4M 1.55% 31

Other funds holding VERA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

MPM BioImpact's VERA Position: Q4 2025 in Review

MPM BioImpact sold out of Vera Therapeutics (VERA) in Q4 2025, closing a stake of 563,075 shares — an estimated $16.4M sold.

MPM BioImpact first reported a position in VERA in Q4 2024 and held it in 4 quarters. The position peaked at $16.4M in Q3 2025. 214 funds tracked by Wall St. Rank hold VERA as of Q4 2025.

  • MPM BioImpact reported no remaining Vera Therapeutics position as of Q4 2025 after selling out during the quarter.
  • MPM BioImpact sold 563,075 Vera Therapeutics shares in Q4 2025, an estimated $16.4M.
  • MPM BioImpact first reported a position in Vera Therapeutics in Q4 2024 and held it in 4 quarters.
  • MPM BioImpact's Vera Therapeutics position peaked at $16.4M in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Vera Therapeutics as of Q4 2025.

Based on MPM BioImpact's 13F filing for Q4 2025, filed 17 Feb 2026.